Clinical trial · Interventional
Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?
"Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?"
NCT07069933CI-TRIAL-00092280not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of Itraconazole as an adjuvant therapy in treatment of patients with acute myeloid Leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Standard care +itraconazole 200mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Control arm
- description
- Standard Care
- interventionNames
- Drug: Chemotherapy
- type
- ACTIVE_COMPARATOR
- label
- Interventional arm
- description
- Standard Care plus itraconazole
- interventionNames
- Drug: Standard care +itraconazole 200mg
Primary outcomes (1)
- measure
- Percentage of blasts in bone marrow at d21 after induction
- timeFrame
- 8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with Acute Myeloid leukemia, and aged 18 years or older 2. Patients whose ECOG performance status ranged from 0-2 and are fit for all treatments protocols Exclusion Criteria: 1. Patients with any other types of malignancies rather than Leukemia and patients. 2. Patients with history alcohol intake, acute or chronic. 3. Patients with documented hypersensitivity or allergy to Itraconazole. 4. Patients suffer from chronic heart failure 5. Patients present with severe dehydration. 6. Patients with severe kidney dysfunction
References
Publications (0)
Data not yet available
No reference posted for this study.